Envestnet Asset Management Inc. reduced its holdings in shares of Diplomat Pharmacy Inc (NYSE:DPLO) by 53.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,311 shares of the company’s stock after selling 6,005 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Diplomat Pharmacy were worth $136,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the company. Legal & General Group Plc lifted its holdings in shares of Diplomat Pharmacy by 2.3% in the 1st quarter. Legal & General Group Plc now owns 100,097 shares of the company’s stock valued at $2,031,000 after purchasing an additional 2,264 shares during the last quarter. Thrivent Financial for Lutherans lifted its holdings in shares of Diplomat Pharmacy by 8.7% in the 1st quarter. Thrivent Financial for Lutherans now owns 32,427 shares of the company’s stock valued at $653,000 after purchasing an additional 2,589 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Diplomat Pharmacy by 2.5% in the 1st quarter. Rhumbline Advisers now owns 116,129 shares of the company’s stock valued at $2,340,000 after purchasing an additional 2,803 shares during the last quarter. OLD National Bancorp IN lifted its holdings in shares of Diplomat Pharmacy by 24.9% in the 2nd quarter. OLD National Bancorp IN now owns 15,791 shares of the company’s stock valued at $404,000 after purchasing an additional 3,148 shares during the last quarter. Finally, Wrapmanager Inc. lifted its holdings in shares of Diplomat Pharmacy by 30.3% in the 2nd quarter. Wrapmanager Inc. now owns 15,362 shares of the company’s stock valued at $393,000 after purchasing an additional 3,576 shares during the last quarter. 80.89% of the stock is owned by institutional investors and hedge funds.

Several analysts have commented on DPLO shares. Morgan Stanley upped their price objective on Diplomat Pharmacy from $16.00 to $21.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 3rd. ValuEngine downgraded Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research note on Monday, July 2nd. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $33.00 price objective on shares of Diplomat Pharmacy in a research note on Friday, June 22nd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the stock. Diplomat Pharmacy has an average rating of “Hold” and a consensus target price of $26.64.

In other news, Director Philip R. Hagerman sold 57,500 shares of the stock in a transaction that occurred on Tuesday, September 11th. The stock was sold at an average price of $19.21, for a total transaction of $1,104,575.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Philip R. Hagerman sold 209,367 shares of the stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $19.07, for a total value of $3,992,628.69. The disclosure for this sale can be found here. 24.70% of the stock is owned by corporate insiders.

DPLO opened at $19.44 on Wednesday. The company has a quick ratio of 0.63, a current ratio of 0.91 and a debt-to-equity ratio of 0.58. The company has a market cap of $1.52 billion, a price-to-earnings ratio of 23.14 and a beta of 1.12. Diplomat Pharmacy Inc has a 52 week low of $14.50 and a 52 week high of $28.74.

Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings data on Monday, August 6th. The company reported $0.17 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.23 by ($0.06). The company had revenue of $1.42 billion for the quarter, compared to analysts’ expectations of $1.42 billion. Diplomat Pharmacy had a net margin of 0.06% and a return on equity of 7.86%. The firm’s revenue was up 25.8% on a year-over-year basis. During the same period in the prior year, the company earned $0.25 earnings per share. equities research analysts expect that Diplomat Pharmacy Inc will post 0.83 earnings per share for the current fiscal year.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Further Reading: Fundamental Analysis and Individual Investors

Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy Inc (NYSE:DPLO).

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.